Mitochondrial-derived peptide humanin as a cytoprotective factor in breast cancer cells.

ASAD AS; IMSEN M; CANDOLFI M; ZUCCATO CF; PIDRE ML; SEILICOVICH A; NICOLA CANDIA AJ; ROMANOWSKI V

Mar del Plata

Congreso; Reunión anual Sociedad Argentina de Investigación Clínica (SAIC) 2019.; 2019

We and others have previously shown that the mitochondrial-derived peptide Humanin (HN) exerts cytoprotection in normal and tumoral cells. HN can be secreted and bind to membrane receptors. Two HN receptors have been identified: (i) a trimeric receptor composed by the ciliary neurotrophic factor receptor (CNTFR), the IL27R (WSX-1) and the 130 kDa glycoprotein (gp130), and (ii) the formyl peptide receptor-like 1 (FPRL-1 or FPR2). We have previously observed that exogenous HN facilitates tumor progression and chemoresistance in experimental triple negative breast cancer (TNBC). Here we performed bioinformatics analysis of transcriptomic databases to assess the expression of mRNA of HN and its receptors in breast cancer specimens. We found expression of HN mRNA in normal human breast tissue and breast tumors specimens of all types, i.e. luminal A, luminal B, HER2+, and TNBC. HN receptors mRNA were also detected in human breast tumors. While the expression of the trimeric receptor subunits was similar in all subtypes of breast tumors, FPR2 expression was highest in TNBC (*p